Krystal Submits Investigational New Drug Application for KB103 Topical Gene Therapy Candidate for Dystrophic … – Investing News Network
Investing News Network |
Krystal Submits Investigational New Drug Application for KB103 Topical Gene Therapy Candidate for Dystrophic …
Investing News Network “KB103 has the potential to become a first-in-class “off-the-shelf” topical gene therapy treatment for DEB. It is the result of an extensive research and preclinical effort by our internal team that included engineering, screening and testing a library … |
